• Vaccine Name: BHV1 gD subunit vaccine
• Target Pathogen: Bovine herpesvirus 1
• Target Disease: Infectious bovine rhinotracheitis
• Vaccine Ontology ID: VO_0004225
• Type: Subunit vaccine
• Status: Research
• Antigen: 25 μg of vaccinia recombinant gD (van et al., 1997).
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001288
  • Description: Avridine
• Immunization Route: Intramuscular injection (i.m.)

Cattle Response

• Vaccination Protocol: Calves were randomly allocated to one of five vaccine groups and immunized with either 25 μg of gD in avridine, 25 μg tgD in avridine, commercial KV, commercial MLV or avridine. All vaccines were administered intramuscularly. 3 weeks after primary immunization the calves were re-immunized (van et al., 1997).
• Immune Response: All vaccinated calves had significantly (P<0.05) higher serum neutralizing antibody titers prechallenge than the control animals. Calves immunized with the experimental gD or tgD vaccines had significantly (P<0.05) higher antibody titers than animals immunized with KV or MLV vaccines (van et al., 1997).
• Challenge Protocol: Calves were challenged 4 weeks after secondary immunization with BHV1. Each calf was exposed for 4 minutes to an aerosol of 10^7 p.f.u. ml- ’ of BHVl strain 108 (van et al., 1997).
• Efficacy: All vaccinated calves had a significantly lower (P<0.05) rectal temperature and sick score than the placebo group. In contrast to the placebo-, KV- and MLV-immunized groups, the gD- and tgD-immunized groups experienced minimal weight loss during the period following challenge. The gD- and tgD-vaccinated calves shed significantly (P<0.05) lower amounts of virus than the placebo or KV-immunized groups throughout the follow-up period. In the gD and tgD subunit vaccine vaccinated groups only one out of eight animals shed virus (van et al., 1997).